Log in

Novelion Therapeutics Stock Price, Forecast & Analysis (NASDAQ:NVLN)

$0.68
0.00 (0.00 %)
(As of 10/24/2019)
Today's Range
$0.68
Now: $0.68
$0.68
50-Day Range
$0.67
MA: $0.69
$0.80
52-Week Range
$0.54
Now: $0.68
$2.35
VolumeN/A
Average Volume200,344 shs
Market Capitalization$13.34 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
Novelion Therapeutics Inc, a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVLN
CUSIPN/A
Phone617-500-7867

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130.43 million
Book Value($4.69) per share

Profitability

Net Income$-108,330,000.00

Miscellaneous

Employees109
Market Cap$13.34 million
Next Earnings DateN/A
OptionableOptionable

Receive NVLN News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter.


Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN."

How were Novelion Therapeutics' earnings last quarter?

Novelion Therapeutics Inc (NASDAQ:NVLN) released its earnings results on Thursday, March, 14th. The biotechnology company reported ($1.03) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.90) by $0.13. The biotechnology company earned $40.71 million during the quarter, compared to analyst estimates of $40.90 million. View Novelion Therapeutics' Earnings History.

Has Novelion Therapeutics been receiving favorable news coverage?

Media coverage about NVLN stock has been trending very negative on Monday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novelion Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View News Stories for Novelion Therapeutics.

Who are some of Novelion Therapeutics' key competitors?

What other stocks do shareholders of Novelion Therapeutics own?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the folowing people:
  • Mr. Benjamin S. Harshbarger, Interim CEO, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Michael D. Price, Exec. VP & CFO (Age 61)
  • Mr. Roger W. Louis, Global Chief Compliance Officer and Head of R&D (Age 63)
  • Ms. Barbara Y. Chan, VP & Chief Accounting Officer (Age 55)
  • Ms. Amanda Murphy, Director of Investor Relations & Corp. Communications

Who are Novelion Therapeutics' major shareholders?

Novelion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include EdgePoint Investment Group Inc. (15.80%). Company insiders that own Novelion Therapeutics stock include Healthcare Master Fun Broadfin and Stonepine Capital, LP. View Institutional Ownership Trends for Novelion Therapeutics.

Which institutional investors are buying Novelion Therapeutics stock?

NVLN stock was acquired by a variety of institutional investors in the last quarter, including EdgePoint Investment Group Inc.. View Insider Buying and Selling for Novelion Therapeutics.

How do I buy shares of Novelion Therapeutics?

Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLN stock can currently be purchased for approximately $0.68.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $13.34 million and generates $130.43 million in revenue each year. Novelion Therapeutics employs 109 workers across the globe.View Additional Information About Novelion Therapeutics.

What is Novelion Therapeutics' official website?

The official website for Novelion Therapeutics is http://www.novelion.com/.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected]


MarketBeat Community Rating for Novelion Therapeutics (NASDAQ NVLN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel